Lexaria Bioscience Corp. LEXX
4.54 USD -0.10 (-2.16%)
Nov 12, 2026, 9:33 AM EST
4.46 Day range 4.78
2.43 52-week range 21.60
- YTD
- -50.97%
- 1 year
- -73.45%
News
benzinga.com Lexaria Bioscience Strikes Agreement With Undisclosed Pharma Firm To Investigate Lexaria's DehydraTECH Technology With One, More PharmCo Modules Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical…
benzinga.com Lexaria Bioscience Completes Enrollment And Continues Dosing On Schedule In Two Oral Semaglutide Pilot Study Comparing DehydraTECH Formulations To Wegovy Tablets Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million. Senti Biosciences…- benzinga.com Lexaria Bioscience Announces Results From Animal Study GLP-1-A26-1 Evaluating Both DehydraTECH-CBD Compositions And DehydraTECH-Semaglutide; Unfortunately, The DHT-SEMA Concentrations In Brain Tissue Were All At Levels Below The Lower Limit Of Quantitation Of The Bioassay Utilized In This Study Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
benzinga.com Dow Tumbles 450 Points; US Small Business Sentiment Declines In August U.S. stocks fell Tuesday, led by a 450-point Dow drop; health care slid while energy rose. NFIB optimism weakened, oil and copper gained.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved…
benzinga.com Lexaria Bioscience Announces Australian Tax Office Pays AU$3.667M In Tax Rebate To Co. Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98…
benzinga.com Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry studyProprietary DehydraTECH 3.0 retatrutide tablet formulation…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
benzinga.com Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know Lexaria Bioscience shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
benzinga.com Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 Industry Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.The MTA details the conditions under which…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-market session. The market value of their outstanding shares is at $6.2 million. Apimeds Pharmaceuticals…
- benzinga.com Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 0 percent. This is a 61.9 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
benzinga.com Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Lexaria Bioscience Receives Ethics Approval For Human GLP-1 Study Comparing Oral DehydraTECH-Semaglutide Formulations To Wegovy, With Dosing Expected To Begin In Mid-June Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an…- benzinga.com Lexaria Bioscience Advances Human Study Of DehydraTECH-Semaglutide Versus Wegovy Tablets Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Lexaria Bioscience Extends Pharma Partnership Through 2026 To Advance GLP-1 Research And DehydraTECH Licensing Potential Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally…
- benzinga.com Lexaria Bioscience Engages The Contract Research Organization To Execute And Report On Its 2026 Animal Study #2 That Will Evaluate A Number Of Formulation Enhancements With Two Next-Generation GLP-1 Drugs In Animals Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization…
- benzinga.com Lexaria Engages CRO To Execute, Report On 2026 Animal Study GLP-1-A26-1 Evaluating Formulation Enhancements Using Both DHT-Sema GLP-1 And DHT-CBD Compositions To Explore Potential For Additional Improved Performance And Stake New IP Claims Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization…
benzinga.com Lexaria Bioscience Q2 EPS $(0.06) Beats $(0.11) Estimate, Sales $20.000K Miss $100.000K Estimate Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 60 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Lexaria Bioscience To Initiate New, Five-Week Human Clinical Study To Evaluate 2 Oral DehydraTECH-Semaglutide Compositions Against Wegovy Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the engagement of the contract research organization ("CRO")…
- benzinga.com Lexaria Bioscience Receives 5 New Patents Including 2 For Diabetes Treatment Utilizing GLP-1 Drugs Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP")…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Lexaria Bioscience Launches 2026 R&D Program With Human And Animal GLP-1 Studies To Expand Drug Delivery IP And Business Opportunities Exciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a…
- benzinga.com Lexaria Bioscience Results From Human Pilot Study, Comparing DehydraTECH-liraglutide Capsules To Injected Saxenda Branded Liraglutide, Achieves 22.7% Reduction In Adverse Events With DHT-LIR As Compared To SAX-LIR Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the…
benzinga.com Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Lexaria Bioscience Reports Final Phase 1b GLP-1-H24-4 Results Showing DHT-Semaglutide Demonstrates Comparable Or Improved Safety, Tolerability And Body Composition vs. Rybelsus Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint…
benzinga.com Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - benzinga.com HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5 HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $4 to $1.5.
benzinga.com Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.- benzinga.com Lexaria Bioscience's DehydraTECH-Semaglutide Shows 48% Reduction In Overall Side Effects And 55% Reduction In Gastrointestinal Side Effects Compared To Rybelsus In Phase 1b Study; Says Recent Financings Support New 2026 Development Opportunities DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus®Recent financings…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session